<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228043</url>
  </required_header>
  <id_info>
    <org_study_id>Apatinib in Colorectal Surgery</org_study_id>
    <nct_id>NCT03228043</nct_id>
  </id_info>
  <brief_title>Apatinib for Resectable Colorectal Cancer</brief_title>
  <official_title>Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanchong Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanchong Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare the outcome of patients with colorectal cancer who treated with
      adjuvant therapy or Apatinib with adjuvant therapy postoperatively.

      Language: English.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants recurrence-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Participants recurrence-free survival in intervention group and control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Participants overall survival in intervention group and control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants recurrence-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of Participants recurrence-free survival in intervention group and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of Participants overall survival in intervention group and control group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Number of Participants recurrence-free survival in intervention group and control group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Number of Participants overall survival in intervention group and control group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants recurrence-free survival</measure>
    <time_frame>4 years</time_frame>
    <description>Number of Participants recurrence-free survival in intervention group and control group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Number of Participants overall survival in intervention group and control group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants recurrence-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Number of Participants recurrence-free survival in intervention group and control group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Number of Participants overall survival in intervention group and control group.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Apatinib</condition>
  <condition>Outcome, Fatal</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Surgery</condition>
  <condition>Adjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Apatinib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal</description>
    <arm_group_label>Apatinib group</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAPEOX</intervention_name>
    <description>CAPEOX adjuvant chemotherapy for resectable colorectal</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>adjuvant chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ECOG performance status score: 0-1.

          2. All colorectal cancer patients underwent curative intent surgery

          3. Patients in stage Ⅱ(Any T, N0, M0) with multiple high-risk factors or stage Ⅲ (any T,
             N1-2, M0) which confirmed by pathology.

          4. Patients who did not receive other treatments for colorectal adenocarcinoma after
             surgery;

          5. The main organ function is good, patients must meet the following requirements with 14
             days before using Apatinib:

               -  blood routine examination:

                    -  hemoglobin&gt; 90 g / L (14 days without blood transfusion);

                    -  neutrophil count&gt; 1.5 x 109 / L;

                    -  platelet count&gt; 100 × 109 / L;

               -  biochemical examination:

                    -  total bilirubin ≤ 1.5 × ULN (normal upper limit);

                    -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2 ×
                       ULN;

                    -  Endogenous creatinine clearance ≥ 60 ml / min (Cockcroft-Gault formula);

               -  Cardiac Doppler Ultrasonography: Left ventricular ejection fraction (LVEF) ≥ 50%.

          6. The surgical incision has been healed, and no bleeding tendency;

          7. Sign informed consent;

          8. Compliance is good, family members agreed to accept survival follow-up.

        Exclusion Criteria:

          1. Patients with other malignancies, except for cured skin basal cell carcinoma and
             cervical cancer in situ.

          2. Participated in other drug clinical trials within four weeks.

          3. Have a variety of factors that affect oral medication (such as unable to swallow,
             chronic diarrhea and intestinal obstruction, etc.).

          4. Have a history of bleeding, screening within 4 weeks before any serious grade to
             CTCAE4.0 3 degrees or more bleeding events.

          5. Patients with central nervous system metastases or a history of central nervous system
             metastases before screening. For patients with suspected central nervous system
             metastases, CT or MRI examinations must be performed within 28 days prior to
             randomization to exclude central nervous system metastasis.

          6. History of high blood pressure can not be controlled with a single antihypertensive
             drug therapy (With a systolic blood pressure&gt; 140 mmHg, diastolic blood pressure&gt; 90
             mmHg. A history of unstable angina within 3 months or a new diagnosis of angina within
             6 months (Including QTcF: male ≥ 450 ms, female ≥470 ms) required long-term use of
             antiarrhythmic drugs and New York Heart Association classification ≥ Class II cardiac
             insufficiency.

          7. Urinary protein ≥ ++ and urine protein&gt; 1.0 g in 24 hours.

          8. Patients with anastomotic fistula, pancreatic fistula or anastomotic stenosis and
             other serious postoperative complications.

          9. Long-term non-healing wounds or bone fractures.

         10. history of organ transplantation.

         11. Imaging shows that the tumor has involved important vascular. Patients in high risk of
             fatal bleeding during treatment.

         12. coagulation abnormalities, with bleeding tendency (14 days before randomization must
             meet: in the absence of anticoagulants, INR in normal range). application of
             anticoagulants or vitamin K antagonists such as warfarin, (1 mg orally, once daily) or
             low-dose aspirin (1 mg or less daily) at a prokaryotic time (INR) ≤ 1.5 Daily
             consumption of not more than 100 mg).

         13. During the last year, the history of tachycardia / venous thrombosis events, such as
             cerebrovascular accident (including transient ischemic attack), deep venous thrombosis
             (due to pre-chemotherapy intravenous thrombosis caused by intravenous thrombosis which
             have been cured ) And pulmonary embolism.

         14. previous thyroid dysfunction, thyroid function can not be maintained within the normal
             range during medication.

         15. with a history of psychiatric drug abuse and can not be prevented or have mental
             disorders.

         16. Have a history of immunodeficiency, or suffer from other acquired, congenital
             immunodeficiency disease, or organ transplant history.

         17. According to the researcher's judgment, there is a serious risk of compromising the
             patient's safety or affecting the patient's completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunhong Tian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanchong Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Limin Zhong</last_name>
    <phone>+8608172712055</phone>
    <email>419314622@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yunhong Tian</name>
      <address>
        <city>Nanchong</city>
        <state>Sichuan</state>
        <zip>637000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunhong Tian, Doctor</last_name>
      <phone>+8613508087719</phone>
      <email>drtianyunhong@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanchong Central Hospital</investigator_affiliation>
    <investigator_full_name>Yunhong Tian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Apatinib</keyword>
  <keyword>Outcome, Fatal</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>surgery</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

